503A vs 503B Pharmacy: What's the Difference for GLP-1s in 2026?
A 503A pharmacy compounds medication for a specific patient under a prescription. A 503B facility produces larger batches under FDA oversight. In 2026, only 503A is the legal pathway for compounded semaglutide and tirzepatide. Here is what each means and why it matters when choosing a GLP-1 platform.
Key takeaways
503A pharmacies compound medications for specific patients under valid prescriptions, regulated by state boards. This is the legal 2026 pathway for compounded GLP-1s.
503B outsourcing facilities produce larger batches under FDA oversight but can no longer legally compound semaglutide (May 2025) or tirzepatide (March 2025).
A platform that does not name its pharmacy makes it impossible to verify whether your medication comes from a compliant 503A source.
PCAB accreditation is a voluntary third-party quality signal for 503A pharmacies — Hallandale Pharmacy, one of Ondra's partners, holds PCAB accreditation.
All of Ondra Health's pharmacy partners are 503A licensed. Their names, license types, and state coverage are listed publicly.
The one-sentence version
A 503A pharmacy compounds medication for a specific patient under a prescription — this is the legal pathway. A 503B facility produced larger batches for distribution — this pathway is now closed for semaglutide and tirzepatide.
503A pharmacies: what they are
Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. A 503A pharmacy operates under a state pharmacy board license, compounds medications only for specific named patients under valid patient-specific prescriptions, follows USP <797> sterile compounding standards for injectables, and may voluntarily seek PCAB accreditation for additional third-party quality verification.
The key phrase is patient-specific prescription. A 503A pharmacy cannot produce a batch of semaglutide vials for general distribution. Each vial must be prepared in response to a prescription for a named patient — meaning the entire supply chain starts with a licensed provider's clinical evaluation.
503B outsourcing facilities: what they are
Section 503B was added to the FD&C Act in 2013. A 503B facility is registered with and inspected by the FDA, can produce compounded medications in larger volumes without patient-specific prescriptions, and must follow FDA Current Good Manufacturing Practice (cGMP) standards. 503B facilities became a significant source of compounded GLP-1s during the 2022–2025 shortage period. That pathway is now closed for GLP-1 medications.
Why 503B is now closed for GLP-1s
FDA enforcement discretion — which allowed 503B compounding during the shortage — ended for tirzepatide on March 19, 2025 and for semaglutide on May 22, 2025. In April 2025, a district court denied a preliminary injunction against FDA enforcement in Outsourcing Facilities Association v. FDA (N.D. Tex.), upholding the FDA's authority. 503B facilities that continue to compound these medications are operating outside current FDA enforcement policy.
Side by side: 503A vs 503B in 2026
503A pharmacy
Regulator: State board of pharmacy
Requires patient-specific Rx: Yes
Batch production allowed: No
FDA inspection: No (state-regulated)
Voluntary accreditation: PCAB (via ACHC)
GLP-1 compounding status (2026): Legal with documented clinical justification
503B outsourcing facility
Regulator: FDA (cGMP standards)
Requires patient-specific Rx: No
Batch production allowed: Yes
FDA inspection: Yes
GLP-1 compounding status (2026): No longer legal for semaglutide or tirzepatide
Why this matters when choosing a platform
When you use a GLP-1 telehealth platform, the type of pharmacy that fills your prescription determines whether your medication is legally compliant. You can only verify this if the pharmacy is named.
Platforms that do not name their pharmacies make this verification impossible. Before starting any compounded GLP-1 program, confirm the pharmacy is identified by name, its license type (503A or 503B) is stated, and you can independently verify its state license and PCAB accreditation.
Ondra Health names all five of its active pharmacy partners publicly with license type, state restrictions, formulation details, and website links — available at ondra.health/pharmacy-partners before you pay anything.
PCAB accreditation: what it adds
PCAB (Pharmacy Compounding Accreditation Board), administered by ACHC, is a voluntary third-party accreditation for 503A pharmacies that goes beyond minimum state licensing. PCAB-accredited pharmacies undergo regular independent audits covering sterility procedures, environmental monitoring, quality testing, and operational controls.
PCAB accreditation does not constitute FDA approval — compounded medications remain not FDA-approved regardless of accreditation status. But it provides an independent quality signal beyond the minimum. Hallandale Pharmacy, one of Ondra's 503A partners, holds PCAB accreditation.
Frequently asked questions
Can a 503B facility still sell compounded GLP-1s to patients?
No. FDA enforcement discretion for 503B tirzepatide compounding ended March 19, 2025 and for semaglutide ended May 22, 2025. 503B facilities compounding these medications are operating outside current FDA policy.
How do I verify whether my pharmacy is 503A or 503B?
The pharmacy should be identified by name. You can then look up its license on the state board of pharmacy website. 503B facilities are also listed on the FDA's registered outsourcing facility database. If your platform does not name the pharmacy, this verification is not possible.
Is 503B medication higher quality than 503A?
Not necessarily — and that's not the relevant question in 2026. The question is legal status. 503A pharmacies following USP <797> standards and holding PCAB accreditation produce high-quality sterile compounded medications. 503B's stricter FDA oversight was about manufacturing scale, not quality superiority. In 2026, 503A is simply the legal pathway for GLP-1 compounding.
Does Ondra Health use 503B pharmacies?
Ondra's pharmacy partners are 503A licensed. White Label/Nova Pharmacy holds dual 503A and 503B licensure, but all GLP-1 prescriptions through Ondra are dispensed under 503A patient-specific prescription pathways.
† This article is for informational purposes only and does not constitute legal advice. Regulatory information is current as of June 2026. The GLP-1 compounding regulatory environment continues to evolve — verify current FDA guidance for the most up-to-date status. Compounded medications are not FDA-approved.